Adherence with Drug Therapy in Pregnancy

Child Health Research Institute, Departments of Pediatrics and Medicine, Children's Hospital, London Health Sciences Centre, The University of Western Ontario, London, ON, Canada N6C 2V5.
Obstetrics and Gynecology International 01/2012; 2012(7419):796590. DOI: 10.1155/2012/796590
Source: PubMed


Available information suggests that nonadherence with medication is a common problem in pregnant women. Not taking prescribed drugs may have potentially negative consequences as patients may not achieve their therapeutic goal. In addition to the many factors that may influence medication-taking behaviour in the general population, unique challenges are encountered in pregnant women as both maternal health and fetal well-being must be considered. On the one hand, pregnant women may be motivated to keep their underlying disease under control, while, on the other hand, fear and anxiety regarding the potential harmful effects of their medication on their unborn child may result in poor adherence with needed medication. Providing evidence-based information, ideally preconceptually, regarding the effects of their medication during pregnancy may be important in avoiding misperceptions that lead to nonadherence.

Full-text preview

Available from:
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Although many medications have documented teratogenic effects, there are relatively little population-based data on perinatal prescription drug use. Methods: Hawaii Pregnancy Risk Assessment Monitoring System (PRAMS) data from 3180 respondents were used to estimate prevalence of overall prescription drug use during and in the month before pregnancy. Data were weighted to be representative of all pregnancies resulting in live births in Hawaii in 2009 and 2010. Vitamins and supplements were excluded from the analysis. Results: Of recently-pregnant women in Hawaii, 18.3% (95%CI: 16.6-20.1) reported using prescription drugs during their most recent pregnancy; 14.5% reported prescription use immediately before pregnancy (95%CI: 13.0-16.1). The most commonly-reported medication types taken during pregnancy were anti-infectives (4.2%; 95%CI: 3.4-5.1), asthma/allergy (3.4%; 95%CI: 2.7-4.3), gastrointestinal (3.3%; 95%CI: 2.5-4.2) and pain relievers (3.2%; 95%CI: 2.5-4.2). Pain relievers (2.8%; 95%CI: 2.2-3.7), asthma/allergy (2.8%; 95%CI: 2.2-3.6), anti-infectives (2.3%; 95%CI: 1.7-3.1) and psychiatric medications (2.2%; 95%CI: 1.6-2.9) were most common before pregnancy. Of women reporting prescription use during pregnancy, 10.0% reported that their healthcare provider had not counseled them during prenatal care on which medicines are safe to use during pregnancy (95%CI: 7.3-13.5). Public Health Implications: As prescription drug use among the general public becomes more widespread, there is an increased need for careful monitoring by health care providers of usage in pregnant and reproductive-aged women. Counseling on potential risks to mother and fetus should be emphasized during prenatal care visits to assure that women are informed and empowered to make the best decisions for themselves and their babies.
    140st APHA Annual Meeting and Exposition 2012; 10/2012
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dramatic increases in the evidence-base for intervention approaches to support antiretroviral therapy (ART) adherence have resulted in numerous reviews, syntheses, and guidelines/recommendations. This review characterizes the current state of the literature and identifies areas in need of additional targeted focus to better align research and practice. Leading recommendations for the process of intervention development (relevant to both rigorous research and real-world intervention planning) and strategies to consider in working with individuals, communities, and systems are provided. In order to move systematically toward the identification of what kinds of interventions work best for whom and when, attending to both intervention outcomes and "drivers" of observed effects or lack of effects in controlled research is critically important. Further, evidence emerging from practice should be aggressively added to research agendas to promote better synergies between the practice and research communities.
    Journal of the International Association of Physicians in AIDS Care (JIAPAC) 01/2013; 12(2). DOI:10.1177/1545109712459041
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Little is known about the impact of pregnancy on response to highly active antiretroviral therapy (HAART) in sub-Saharan Africa. We examined the effect of incident pregnancy after HAART initiation on clinical response to HAART. We evaluated a prospective clinical cohort of adult women initiating HAART in Johannesburg, South Africa between 1 April 2004 and 31 March 2011, and followed up until an event, transfer, drop-out, or administrative end of follow-up on 30 September 2011. Women over age 45 and women who were pregnant at HAART initiation were excluded from the study. Main exposure was having experienced pregnancy after HAART initiation; main outcome was death and (separately) death or new AIDS event. We calculated adjusted hazard ratios (HRs) and 95% confidence limits (CL) using marginal structural Cox proportional hazards models. The study included 7,534 women, and 20,813 person-years of follow-up; 918 women had at least one recognized pregnancy during follow-up. For death alone, the weighted (adjusted) HR was 0.84 (95% CL 0.44, 1.60). Sensitivity analyses confirmed main results, and results were similar for analysis of death or new AIDS event. Incident pregnancy was associated with a substantially reduced hazard of drop-out (HR = 0.62, 95% CL 0.51, 0.75). Recognized incident pregnancy after HAART initiation was not associated with increases in hazard of clinical events, but was associated with a decreased hazard of drop-out. High rates of pregnancy after initiation of HAART may point to a need to better integrate family planning services into clinical care for HIV-infected women.
    PLoS ONE 03/2013; 8(3):e58117. DOI:10.1371/journal.pone.0058117 · 3.23 Impact Factor
Show more